For: | Ng JJJ, Loo WM, Siah KTH. Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2023; 15(7): 925-938 [PMID: 37547029 DOI: 10.4254/wjh.v15.i7.925] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v15/i7/925.htm |
Number | Citing Articles |
1 |
Mihaela Rotaru, Ana-Maria Singeap, Alin Ciobica, Laura Huiban, Carol Stanciu, Laura Romila, Vasile Burlui, Ioannis Mavroudis, Anca Trifan. Oral Health and “Modern” Digestive Diseases: Pathophysiologic and Etiologic Factors. Biomedicines 2024; 12(8): 1854 doi: 10.3390/biomedicines12081854
|
2 |
Giovanni Tarantino, Vincenzo Citro. Crosstalk Between the Spleen and Other Organs/Systems: Downstream Signaling Events. Immuno 2024; 4(4): 479 doi: 10.3390/immuno4040030
|
3 |
Md. Musab Khalil, Sirajam Munira, Md. Mahbubul Alam, Al Mahmood Appolo, Musatafa Md. Abu Sayeed, Atikul Islam, Narwana Khaleque, Mohammad Faisal, Arifa Tasnim, Ruma Najnin, Mahmudur Rahman, Enamul Karim, Md. Golam Kibria. Prevalence of Nonalcoholic Fatty Liver Disease [NAFLD] and Metabolic dysfunction associated Fatty Liver Disease [MAFLD] in patients with Irritable Bowel Syndrome [IBS]. SN Comprehensive Clinical Medicine 2024; 6(1) doi: 10.1007/s42399-024-01675-5
|
4 |
Federica Fogacci, Marina Giovannini, Valentina Di Micoli, Elisa Grandi, Claudio Borghi, Arrigo Francesco Giuseppe Cicero. Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Nutrients 2024; 16(15): 2454 doi: 10.3390/nu16152454
|